RASA1 sirna

RASA1 siRNA (Human)

Cat. Num. AAA8204459

• Gene Names: RASA1; GAP; PKWS; RASA; CMAVM; CM-AVM; RASGAP; p120GAP; p120RASGAP
• Reactivity: Human
• Applications: RNA Interference (RNAi)
• Purity: > 97%
• Synonyms: RASA1; RASA1 siRNA (Human); GAP; RASA; Ras GTPase-activating protein 1; GTPase-activating protein; RasGAP; Ras p21 protein activator; p120GAP; RASA1 sirna

• Host: Synthetic
• Reactivity: Human
• Specificity: RASA1 siRNA (Human) is a target-specific 19-23 nt siRNA oligo duplexes designed to knock down gene expression.
• Purity/Purification: > 97%
• Form/Format: Lyophilized powder
• Sequence Length: 1047

• Applicable Applications for RASA1 sirna: RNA Interference (RNAi)
• Quality Control: Oligonucleotide synthesis is monitored base by base through trityl analysis to ensure appropriate coupling efficiency. The oligo is subsequently purified by affinity-solid phase extraction. The annealed RNA duplex is further analyzed by mass spectrometry to verify the exact composition of the duplex. Each lot is compared to the previous lot by mass spectrometry to ensure maximum lot-to-lot consistency.
• Directions for Use: We recommends transfection with 100 nM siRNA 48 to 72 hours prior to cell lysis. Before resuspending, briefly centrifuge the tube to ensure the lyophilized siRNA is at the bottom of the tube. Resuspend the siRNA oligos to an appropriate concentration with DEPC water. For each vial, suitable for 250 transfections in 24 well plate (20 pmol for each well).
• Components: We offer pre-designed sets of 3 different target-specific siRNA oligo duplexes of human RASA1 gene. Each vial contains 5 nmol of lyophilized siRNA. The duplexes can be transfected individually or pooled together to achieve knockdown of the target gene, which is most commonly assessed by qPCR or western blot. Our siRNA oligos are also chemically modified (2'-OMe) at no extra charge for increased stability and enhanced knockdown in vitro and in vivo.
• Preparation and Storage: Shipped at 4 degree C. Store at -20 degree C for one year.

Related Product Information for RASA1 sirna

siRNA to inhibit RASA1 expression using RNA interference

NCBI and Uniprot Product Information

• NCBI GI #: 4506431
• NCBI GeneID: 5921
• NCBI Accession #: NP_002881.1
• NCBI GenBank Nucleotide #: NM_002890.2
• UniProt Accession #: P20936; Q68CU6; Q9UDI1; B2R6W3; B4DTL2
• Molecular Weight: 101,546 Da
• NCBI Official Full Name: ras GTPase-activating protein 1 isoform 1
• NCBI Official Synonym Full Names: RAS p21 protein activator (GTPase activating protein) 1
• NCBI Official Symbol: RASA1
• NCBI Official Synonym Symbols: GAP; PKWS; RASA; CMAVM; CM-AVM; RASGAP; p120GAP; p120RASGAP
• NCBI Protein Information: ras GTPase-activating protein 1
• UniProt Protein Name: Ras GTPase-activating protein 1
• Protein Family: Ras GTPase-activating protein
• UniProt Gene Name: RASA1
• UniProt Synonym Gene Names: GAP; RASA; GAP; GTPase-activating protein; RasGAP
• UniProt Entry Name: RASA1_HUMAN

NCBI Description

The protein encoded by this gene is located in the cytoplasm and is part of the GAP1 family of GTPase-activating proteins. The gene product stimulates the GTPase activity of normal RAS p21 but not its oncogenic counterpart. Acting as a suppressor of RAS function, the protein enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with basal cell carcinomas. Mutations also have been associated with hereditary capillary malformations (CM) with or without arteriovenous malformations (AVM) and Parkes Weber syndrome. Alternative splicing results in two isoforms where the shorter isoform, lacking the N-terminal hydrophobic region but retaining the same activity, appears to be abundantly expressed in placental but not adult tissues. [provided by RefSeq, May 2012]

Uniprot Description

RASA1: a GTPase activator for normal RAS p21 but not its oncogenic counterpart, converting it to the putatively inactive GDP-bound state. Acting as a suppressor of RAS function, it enhances the weak intrinsic GTPase activity of RAS proteins resulting in the inactive GDP-bound form of RAS, thereby allowing control of cellular proliferation and differentiation. Mutations leading to changes in the binding sites of either protein are associated with basal cell carcinomas. Two alternatively spliced isoforms have been described.

Protein type: Motility/polarity/chemotaxis; GAPs, Ras; Oncoprotein; GAPs

Chromosomal Location of Human Ortholog: 5q13.3

Cellular Component: ruffle; cytoplasm; cytosol

Molecular Function: GTPase binding; protein binding; potassium channel inhibitor activity; glycoprotein binding; receptor binding

Biological Process: axon guidance; negative regulation of cell adhesion; negative regulation of cell-matrix adhesion; signal transduction; regulation of cell shape; regulation of actin filament polymerization; embryonic development; cytokinesis after mitosis; regulation of RNA metabolic process; ephrin receptor signaling pathway; negative regulation of Ras protein signal transduction; blood vessel morphogenesis; negative regulation of neuron apoptosis; vasculogenesis; vascular endothelial growth factor receptor signaling pathway

Disease: Parkes Weber Syndrome; Capillary Malformation-arteriovenous Malformation; Basal Cell Carcinoma, Susceptibility To, 1